Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism

Dean Y. Maeda, Mark T. Quinn, Igor A. Schepetkin, Liliya N. Kirpotina, John A. Zebala

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The chemokine receptors CXCR1/2 are involved in a variety of inflammatory diseases, including chronic obstructive pulmonary disease. Several classes of allosteric small-molecule CXCR1/2 antagonists have been developed. The data presented here describe the cellular pharmacology of the acid and ester forms of the nicotinamide glycolate pharmacophore, a potent antagonist of CXCR2 signaling by the chemokines CXCL1 and CXCL8. Ester forms of the nicotinamide glycolate antagonized CXCL1-stimulated chemotaxis (IC50 = 42 nM) and calcium flux (IC50 = 48 nM) in human neutrophils, but they were inactive in cell-free assays of 125I-CXCL8/ CXCR2 binding and CXCL1-stimulated guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) exchange. Acid forms of the nicotinamide glycolate were inactive in whole-cell assays of chemotaxis and calcium flux, but they inhibited 125ICXCL8/ CXCR2 binding and CXCL1-stimulated [ 35S]GTPγS exchange. The 3H ester was internalized by neutrophils and rapidly converted to the 3H acid in a concentrative process. The 3H acid was not internalized by neutrophils but was sufficient alone to inhibit CXCL1-stimulated calcium flux in neutrophils that were permeabilized by electroporation to permit its direct access to the cell interior. Neutrophil efflux of the acid was probenecid-sensitive, consistent with an organic acid transporter. These data support a mechanism wherein the nicotinamide glycolate ester serves as a lipophilic precursor that efficiently translocates into the intracellular neutrophil space to liberate the active acid form of the pharmacophore, which then acts at an intracellular site. Rapid inactivation by plasma esterases precluded use in vivo, but the mechanism elucidated provided insight for new nicotinamide pharmacophore classes with therapeutic potential.

Original languageEnglish
Pages (from-to)145-152
Number of pages8
JournalJournal of Pharmacology and Experimental Therapeutics
Volume332
Issue number1
DOIs
Publication statusPublished - Jan 2010
Externally publishedYes

Fingerprint

Glycolates
glycolic acid
Niacinamide
Neutrophils
Acids
Esters
Chemotaxis
Calcium
Inhibitory Concentration 50
Chemokine CXCL1
Intracellular Space
Guanosine 5'-O-(3-Thiotriphosphate)
Probenecid
Electroporation
Chemokine Receptors
Esterases
Interleukin-8
Chronic Obstructive Pulmonary Disease
Pharmacology

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism. / Maeda, Dean Y.; Quinn, Mark T.; Schepetkin, Igor A.; Kirpotina, Liliya N.; Zebala, John A.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 332, No. 1, 01.2010, p. 145-152.

Research output: Contribution to journalArticle

Maeda, Dean Y. ; Quinn, Mark T. ; Schepetkin, Igor A. ; Kirpotina, Liliya N. ; Zebala, John A. / Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism. In: Journal of Pharmacology and Experimental Therapeutics. 2010 ; Vol. 332, No. 1. pp. 145-152.
@article{a43aca6ba056449d93edffd2ddc89b98,
title = "Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism",
abstract = "The chemokine receptors CXCR1/2 are involved in a variety of inflammatory diseases, including chronic obstructive pulmonary disease. Several classes of allosteric small-molecule CXCR1/2 antagonists have been developed. The data presented here describe the cellular pharmacology of the acid and ester forms of the nicotinamide glycolate pharmacophore, a potent antagonist of CXCR2 signaling by the chemokines CXCL1 and CXCL8. Ester forms of the nicotinamide glycolate antagonized CXCL1-stimulated chemotaxis (IC50 = 42 nM) and calcium flux (IC50 = 48 nM) in human neutrophils, but they were inactive in cell-free assays of 125I-CXCL8/ CXCR2 binding and CXCL1-stimulated guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) exchange. Acid forms of the nicotinamide glycolate were inactive in whole-cell assays of chemotaxis and calcium flux, but they inhibited 125ICXCL8/ CXCR2 binding and CXCL1-stimulated [ 35S]GTPγS exchange. The 3H ester was internalized by neutrophils and rapidly converted to the 3H acid in a concentrative process. The 3H acid was not internalized by neutrophils but was sufficient alone to inhibit CXCL1-stimulated calcium flux in neutrophils that were permeabilized by electroporation to permit its direct access to the cell interior. Neutrophil efflux of the acid was probenecid-sensitive, consistent with an organic acid transporter. These data support a mechanism wherein the nicotinamide glycolate ester serves as a lipophilic precursor that efficiently translocates into the intracellular neutrophil space to liberate the active acid form of the pharmacophore, which then acts at an intracellular site. Rapid inactivation by plasma esterases precluded use in vivo, but the mechanism elucidated provided insight for new nicotinamide pharmacophore classes with therapeutic potential.",
author = "Maeda, {Dean Y.} and Quinn, {Mark T.} and Schepetkin, {Igor A.} and Kirpotina, {Liliya N.} and Zebala, {John A.}",
year = "2010",
month = "1",
doi = "10.1124/jpet.109.159020",
language = "English",
volume = "332",
pages = "145--152",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Nicotinamide glycolates antagonize CXCR2 activity through an intracellular mechanism

AU - Maeda, Dean Y.

AU - Quinn, Mark T.

AU - Schepetkin, Igor A.

AU - Kirpotina, Liliya N.

AU - Zebala, John A.

PY - 2010/1

Y1 - 2010/1

N2 - The chemokine receptors CXCR1/2 are involved in a variety of inflammatory diseases, including chronic obstructive pulmonary disease. Several classes of allosteric small-molecule CXCR1/2 antagonists have been developed. The data presented here describe the cellular pharmacology of the acid and ester forms of the nicotinamide glycolate pharmacophore, a potent antagonist of CXCR2 signaling by the chemokines CXCL1 and CXCL8. Ester forms of the nicotinamide glycolate antagonized CXCL1-stimulated chemotaxis (IC50 = 42 nM) and calcium flux (IC50 = 48 nM) in human neutrophils, but they were inactive in cell-free assays of 125I-CXCL8/ CXCR2 binding and CXCL1-stimulated guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) exchange. Acid forms of the nicotinamide glycolate were inactive in whole-cell assays of chemotaxis and calcium flux, but they inhibited 125ICXCL8/ CXCR2 binding and CXCL1-stimulated [ 35S]GTPγS exchange. The 3H ester was internalized by neutrophils and rapidly converted to the 3H acid in a concentrative process. The 3H acid was not internalized by neutrophils but was sufficient alone to inhibit CXCL1-stimulated calcium flux in neutrophils that were permeabilized by electroporation to permit its direct access to the cell interior. Neutrophil efflux of the acid was probenecid-sensitive, consistent with an organic acid transporter. These data support a mechanism wherein the nicotinamide glycolate ester serves as a lipophilic precursor that efficiently translocates into the intracellular neutrophil space to liberate the active acid form of the pharmacophore, which then acts at an intracellular site. Rapid inactivation by plasma esterases precluded use in vivo, but the mechanism elucidated provided insight for new nicotinamide pharmacophore classes with therapeutic potential.

AB - The chemokine receptors CXCR1/2 are involved in a variety of inflammatory diseases, including chronic obstructive pulmonary disease. Several classes of allosteric small-molecule CXCR1/2 antagonists have been developed. The data presented here describe the cellular pharmacology of the acid and ester forms of the nicotinamide glycolate pharmacophore, a potent antagonist of CXCR2 signaling by the chemokines CXCL1 and CXCL8. Ester forms of the nicotinamide glycolate antagonized CXCL1-stimulated chemotaxis (IC50 = 42 nM) and calcium flux (IC50 = 48 nM) in human neutrophils, but they were inactive in cell-free assays of 125I-CXCL8/ CXCR2 binding and CXCL1-stimulated guanosine 5′-O-(3-[35S]thio)triphosphate ([35S]GTPγS) exchange. Acid forms of the nicotinamide glycolate were inactive in whole-cell assays of chemotaxis and calcium flux, but they inhibited 125ICXCL8/ CXCR2 binding and CXCL1-stimulated [ 35S]GTPγS exchange. The 3H ester was internalized by neutrophils and rapidly converted to the 3H acid in a concentrative process. The 3H acid was not internalized by neutrophils but was sufficient alone to inhibit CXCL1-stimulated calcium flux in neutrophils that were permeabilized by electroporation to permit its direct access to the cell interior. Neutrophil efflux of the acid was probenecid-sensitive, consistent with an organic acid transporter. These data support a mechanism wherein the nicotinamide glycolate ester serves as a lipophilic precursor that efficiently translocates into the intracellular neutrophil space to liberate the active acid form of the pharmacophore, which then acts at an intracellular site. Rapid inactivation by plasma esterases precluded use in vivo, but the mechanism elucidated provided insight for new nicotinamide pharmacophore classes with therapeutic potential.

UR - http://www.scopus.com/inward/record.url?scp=73949152536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949152536&partnerID=8YFLogxK

U2 - 10.1124/jpet.109.159020

DO - 10.1124/jpet.109.159020

M3 - Article

C2 - 19779130

AN - SCOPUS:73949152536

VL - 332

SP - 145

EP - 152

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -